Literature DB >> 20080487

Growth factors as active participants in carcinogenesis: a perspective.

J Halper1.   

Abstract

Growth factors are low molecular peptides active in the stimulation of cell proliferation and in the regulation of embryonic development and cellular differentiation. Significant progress has been made in developing effective strategies to treat human malignancies with new chemical compounds based on a rationale directed against various components of signaling pathways. Many of these drugs target a growth factor receptor--for instance, in the form of monoclonal antibodies or inhibitors of tyrosine kinases, such as monoclonal antibodies against epidermal growth factor receptors used in treating certain types of breast cancer. Imatinib mesylate [Gleevec]) is an excellent example of mediators of signal transduction, such as tyrosine kinases. Growth factors proper are used to ameliorate various and sometimes fatal side effects of cytotoxic and/or myelosuppressive chemotherapy. Basic characteristics of several growth families are discussed with therapeutic modalities based on growth factor activity or, more often, inhibition of such activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20080487     DOI: 10.1177/0300985809352981

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  17 in total

1.  Growth Factor Roles in Soft Tissue Physiology and Pathophysiology.

Authors:  Jennifer H Roberts; Jaroslava Halper
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Lewis Y promotes growth and adhesion of ovarian carcinoma-derived RMG-I cells by upregulating growth factors.

Authors:  Feifei Li; Bei Lin; Yingying Hao; Yan Li; Juanjuan Liu; Jianping Cong; Liancheng Zhu; Qing Liu; Shulan Zhang
Journal:  Int J Mol Sci       Date:  2010-09-29       Impact factor: 5.923

3.  Silibinin inhibits VEGF secretion and age-related macular degeneration in a hypoxia-dependent manner through the PI-3 kinase/Akt/mTOR pathway.

Authors:  C H Lin; C H Li; P L Liao; L S Tse; W K Huang; H W Cheng; Y W Cheng
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma.

Authors:  Martin J Edelman; Josephine Feliciano; Binbin Yue; Pablo Bejarano; Olga Ioffe; David Reisman; Douglas Hawkins; Qiwei Gai; David Hicks; Ginette Serrero
Journal:  Hum Pathol       Date:  2014-06-05       Impact factor: 3.466

5.  Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA.

Authors:  Ke Xiao; Zhengxiao Ouyang; Hui-Huan Tang
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

6.  Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.

Authors:  Ginette Serrero; Douglas M Hawkins; Binbin Yue; Olga Ioffe; Pablo Bejarano; Jeffrey T Phillips; Jonathan F Head; Robert L Elliott; Katherine R Tkaczuk; Andrew K Godwin; Joellen Weaver; Wes E Kim
Journal:  Breast Cancer Res       Date:  2012-02-08       Impact factor: 6.466

7.  Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway.

Authors:  Wenwen Xu; Jim Jun-hui Huang; Peter Chi Keung Cheung
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

8.  Assessing the Angiogenic Efficacy of Pleiotrophin Released from Injectable Heparin-Alginate Gels.

Authors:  Isobel Rountree; Collin Polucha; Kareen L K Coulombe; Fabiola Munarin
Journal:  Tissue Eng Part A       Date:  2021-02-22       Impact factor: 4.080

9.  Simultaneous application of bevacizumab and anti-CTGF antibody effectively suppresses proangiogenic and profibrotic factors in human RPE cells.

Authors:  Abouzar Bagheri; Zahra-Soheila Soheili; Hamid Ahmadieh; Shahram Samiei; Nader Sheibani; Shamila Darvishalipour Astaneh; Mozhgan Rezaei Kanavi; Azam Mohammadian
Journal:  Mol Vis       Date:  2015-04-10       Impact factor: 2.367

Review 10.  Stimuli-Responsive Delivery of Growth Factors for Tissue Engineering.

Authors:  Moyuan Qu; Xing Jiang; Xingwu Zhou; Canran Wang; Qingzhi Wu; Li Ren; Jixiang Zhu; Songsong Zhu; Peyton Tebon; Wujin Sun; Ali Khademhosseini
Journal:  Adv Healthc Mater       Date:  2020-03-03       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.